The Team
The entire Ethismos team is dedicated to advancing and developing safe and effective therapies for the prevention of chronic pain and treatment of chronic pain that will have a positive impact on the lives of patients and their families. To this end, Ethismos seeks to provide physicians and 3rd party payers with regimens to prevent and treat chronic pain, the costliest diagnosis to the US healthcare system (Gaskin et al., 2012).
The Ethismos team have years of development experience with the serotonin preferring triple reuptake inhibitor, amitifadine and recent success with the sister triple reuptake inhibitor, centanafadine, a norepinephrine preferring triple for ADHD now in Phase 3 with Otsuka Pharmaceutical Development & Commercialization, Inc.
Ethismos has brought together many of the same team of scientists and development experts who advanced centanafadine from pre-IND through the end of Phase 2 stage prior to the sale to Otsuka by Ethismos' predecessor company Neurovance (now owned by Otsuka).
Anthony McKinney – Founder & CEO
An industry veteran with over 30 years of biotechnology and pharma experience, Anthony has held senior positions in several successful emerging and established pharma/biotech companies including Du Pont Merck, Texas Biotechnology Corp (acquired by Pfizer), Novazyme (acquired by Genzyme), and Genzyme, a leading global biotechnology giant later acquired by Sanofi. Anthony was a founding executive at Orexigen Therapeutics, a biotechnology company, and founding CEO of Euthymics and Neurovance, predecessor companies to Ethismos.
Anthony has played lead roles in the founding and growth of high-potential early-stage biotechnology companies and has a track record of adding shareholder value to emerging biotech companies through strategic partnerships and successful exits.
During a 34-year career Anthony has led sales and market research teams, directed product development efforts, and managed corporate development functions. McKinney has 16 issued US patents, multiple scientific publications, major involvement in two US drug approvals, and participated in raising over $300 million in private and public financing. Anthony brings a unique blend of business and science to the CEO role.
Board of Directors - - Ethismos has assembled a talented group of outside directors to advise and guide on fund raising, organization, and development. As a group they are a wealth of knowledge and provide a key competitive advantage as Ethismos accelerates growth and advances toward landmark events.
